This article was originally published in The Gray Sheet
Early stage cardiovascular device firm completes a $12.8 mil. private financing round. Under development is the HeartStent direct revascularization device intended for coronary artery disease patients currently treated with coronary artery bypass grafts. The less invasive system is placed "through the ventricular wall" to supply blood to a coronary artery directly from the left ventricle of the heart, the St. Paul, Minnesota firm explains. Pre-clinical studies "prove feasibility" of the approach, which eliminates the need for artery or vein harvesting, cuts procedure time, and can be performed on a beating heart, HeartStent claims. Lead investors include Kleiner Perkins, Technology Partners, U.S. Bancorp Piper Jaffray Ventures, St. Paul Ventures, and Charter Growth Capital
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.